ABVC BioPharma Closes $3.39 Million Private Placement to Fund Subsidiaries and Settle Lind Global Claim

ABVC BioPharma's $3.39 million private placement of original issue discount convertible notes provides working capital, subsidiary funding, and a $625,000 settlement with Lind Global Fund II LP, supporting its broader strategy to advance its pharmaceutical and medical-device portfolio through independent financing.

Chicago Metrowire Staff
••Business
ABVC BioPharma Closes $3.39 Million Private Placement to Fund Subsidiaries and Settle Lind Global Claim

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the closing of a private placement of original issue discount senior convertible promissory notes with institutional and other accredited investors, generating aggregate gross proceeds of approximately $3.39 million before placement agent fees and other offering expenses. The notes carry an aggregate principal amount of $4,106,060, mature on June 30, 2027, and become convertible eight months after issuance into common stock at 85% of the average of the three volume-weighted average prices for the three trading days immediately prior to conversion, subject to a floor price and adjustments.

The company expects to use net proceeds for general working capital, funding of its subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP under a definitive release and settlement agreement. That payment is expected to satisfy specified outstanding claims and support ABVC's ability to pursue broader financing and business development initiatives. The offering is also intended to advance ABVC's strategy of developing its pharmaceutical and medical-device portfolio through strategic licensing, subsidiary development, and independent financing.

ABVC has established dedicated business platforms across its principal development areas: AiBtl BioPharma Inc. for central nervous system drug programs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic medical-device development and commercialization, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services as well as an AI biotechnology innovation platform. Through these arrangements, the company seeks to advance development programs while creating opportunities for licensing revenues, milestone payments, future royalties, and equity value.

The transaction matters because it addresses near-term liquidity and resolves a specified payment obligation while keeping ABVC's subsidiary-based financing model intact. The company continues to evaluate potential strategic financing and capital-market opportunities for its affiliated businesses as a means to support long-term development and commercialization objectives. WallachBeth Capital, Inc. acted as placement agent, Hunter Taubman Fischer & Li LLC acted as legal counsel to the company, and Sichenzia Ross Ference Carmel LLP acted as counsel to the placement agent.

The notes and underlying shares have not been registered under the Securities Act of 1933 or state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption. Additional details will be available in the company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. The original release is available through www.newmediawire.com.

Blockchain Registration

QR Code for Blockchain Registration